Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.

Abstract

BACKGROUND Rates and impacts of worsening symptoms in patients with psoriasis have not been well characterized. OBJECTIVES To assess the risk of clinically relevant worsening of psoriasis symptoms in patients treated with adalimumab versus placebo and to determine the health-related quality-of-life (HRQOL) impacts of such worsening. METHODS The… (More)
DOI: 10.2165/11539360-000000000-00000

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.